Celgene

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.

Juno Therapeutics

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users. It costs $163,381 per year for the average patient.

Revlimid

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

New Linde PLC

McDonald's

Activision Blizzard

H&R Block

AT&T

Tiffany & Co.

Pioneer Investment Management sold shares of the following stocks during the fourth quarter of 2019.

Pioneer Investments Cuts Linde, McDonald’s

Bristol-Myers

Before the market opened on Feb. 6, Bristol-Myers Squibb (NYSE:BMY) reported earnings for the fourth quarter and full-year 2019.

Bristol-Myers Squibb Smashes Earnings Predictions Following Celgene Acquisition

The pharmaceutical giant's guidance also looks good.

Bristol-Myers Squibb's Earnings Get a Boost From Celgene Acquisition

Not enough defendants were willing to sign onto the class action.

Bristol-Myers Squibb's Celgene Unit Backs Out of a $55 Million Settlement

One of my better investments of 2019 was Celgene (NASDAQ:CELG), which was acquired by Bristol-Myers (NYSE:BMY).

An Unusual Investment With 125% Upside

Gilead Sciences

But the big biotech isn't a happy camper about its contribution.

How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition

Will this pharmaceutical giant be able to grow through Celgene’s patent cliff? Perhaps not, but it's still worth an investment.

Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?

AbbVie

Allergan

Eli Lilly

Medicines

Merck

Novartis

Pfizer

Sanofi

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020

Don't sleep on this newly formed pharma giant.

After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright

Editas Medicine

An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.

Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable

Pharmaceutical company Bristol-Myers has risen this year despite shareholder opposition to its Celgene buyout. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock?

Bristol-Myers Has Now Acquired Celgene — So, Should You Buy BMY Stock?

There are two reasons this Fool isn't selling his newfound shares from the Celgene buyout.

Why I'm Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed

Bristol-Myers Squibb Co. BMY, -0.12% on Wednesday said it completed its $74 billion acquisition of Celgene Corp.

Bristol-Myers Squibb completes $74 billion acquisition of Celgene

Celgene: Bargain Bin At Bristol-Myers Squibb Deal Closing

Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.

Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.

Bristol-Myers Gets FTC Clearance for Celgene Acquisition

Celgene Corp. CELG, +0.00% is required to divest its most popular psoriasis treatment in order to be acquired by Bristol-Myers Squibb Co.

FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition

Bristol-Myers Squibb and Celgene said late Friday the U.S. Federal Trade Commission cleared their looming merger.

Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.

Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Biogen

DaVita

Edwards Lifesciences

HCA Healthcare

Incyte

Teleflex

Health Care Select Sector SPDR Fund

DENTSPLY SIRONA

These are the health care stocks with the best value, fastest growth, and most momentum for November.

Top Health Care Stocks for November 2019

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

Alexion Pharma

Gildan Activewear

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs See Rising Tide in Short Interest (Nov 12)

Good news for Celgene is good news for Bristol-Myers Squibb -- and investors who like the big drugmaker's juicy dividend.

Why Celgene's Latest FDA Approval Makes Bristol-Myers Squibb's Dividend Look Even Better

ACADIA Pharma

Coherus BioSciences

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

4 Biotech Stocks That Could Keep Beating Wall Street

Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

News for Celgene Stock (CELG)